Cannabidiol as a pharmacological intervention in attention deficit hyperactivity disorder (ADHD): a narrative review
Abstract
Introduction: attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, impulsivity, and hyperactivity, impacting social and academic performance. Conventional treatment includes stimulant and non-stimulant medications, along with cognitive-behavioral therapy, but side effects may limit adherence. Objective: to review the literature on the use of cannabidiol (CBD) in the treatment of ADHD. Methods: a narrative literature review through searches in scientific databases, including experimental and clinical studies evaluating the effects of CBD in animal models and human subjects. Results: animal studies demonstrated reduced hyperactivity and improved social behavior, without significant changes in attention. In a clinical trial with adults, CBD treatment improved impulsivity and showed a trend toward better attention. Conclusion: although findings are promising, further controlled clinical studies are needed to confirm the efficacy and safety of cannabidiol in ADHD management.
Downloads
References
Dallabrida CG, Bender JMO, Chade ES, Rodrigues N, Sampaio TB. Endocannabinoid system changes throughout life: implications and therapeutic potential for autism, ADHD, and Alzheimer’s disease. Brain Sci. 2024;14(6):592.
Kirkland AE, Fadus MC, Gruber SA, Gray KM, Wilens TE, Squeglia LM. A scoping review of the use of cannabidiol in psychiatric disorders. Psychiatry Res. 2022;308:114–122.
Kaplan JS, Wagner JK, Reid K, McGuinness F, Arvila S, Brooks M, et al. Cannabidiol exposure during the mouse adolescent period is without harmful behavioral effects on locomotor activity, anxiety, and spatial memory. Front Behav Neurosci. 2021;15:1–9.
Asherson P, Buitelaar J, Faraone SV, Rohde LA. Adult attention-deficit hyperactivity disorder: key conceptual issues. Lancet Psychiatry. 2016;3:568–78.
Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet. 2020;395(10222):450–62. doi:10.1016/S0140-6736(19)33004-1.
Associação Psiquiátrica Americana. Manual diagnóstico e estatístico de transtornos mentais: DSM-5. 5ª ed. Arlington: Associação Psiquiátrica Americana; 2014. p.59–65.
Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016;387(10024):1240–50.
Palacio JD, De la Peña-Olvera F, Palacios-Cruz L, Ortiz-León S. Algoritmo latinoamericano de tratamiento multimodal del trastorno por déficit de atención e hiperactividad (TDAH) a través de la vida. Rev Colomb Psiquiatr. 2009;38:35–65.
John D, Madelyn H. Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J Nutr. 2007;137(6):1539S–47S. https://doi.org/10.1093/jn/137.6.1539S
Cortese S, Kelly C, Chabernaud C, Proal E, Di Martino A, Milham MP, Castellanos FX. Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies. Am J Psychiatry. 2012;169(10):1038–55.
Bonini SA, Premoli M, Tambaro S, Kumar A, Maccarinelli G, Memo M, Mastinu A. Cannabis sativa: a comprehensive ethnopharmacological review of a medicinal plant with a long history. J Ethnopharmacol. 2018;227:300–15.
Alves P, Amaral C, Teixeira N, Correia-da-Silva G. Cannabis sativa: much more beyond Δ9-tetrahydrocannabinol. Pharmacol Res. 2020;157:104822.
Naya NM, Kelly J, Corna G, Golino M, Abbate A, Toldo S. Molecular and cellular mechanisms of action of cannabidiol. Molecules. 2023;28(16):59–80. https://pmc.ncbi.nlm.nih.gov/articles/PMC10458707/
Knaub K, Sartorius T, Dharsono T, Wacker R, Wilhelm M, Schon C. A novel self-emulsifying drug delivery system (SEDDS) based on VESIsorb® formulation technology improving the oral bioavailability of cannabidiol in healthy subjects. Molecules. 2019;24(16):2967.
Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32:1053–67.
Zamberletti E, Gabaglio M, Parolaro D. The endocannabinoid system and autism spectrum disorders: insights from animal models. Int J Mol Sci. 2017;18(9):1916.
Parrella NF, Hill AT, Enticott PG, Barhoun P, Bower IS, Ford TC. A systematic review of cannabidiol trials in neurodevelopmental disorders. Pharmacol Biochem Behav. 2023;230:173–89.
Pacher P, Konus G. Modulating the endocannabinoid system in human health and disease – successes and failures. FEBS J. 2013;280(9):1918–43.
Aitta-Aho A, Maksimovic M, Dahl K, Sprengel R, Korpi ER. Attenuation of novelty-induced hyperactivity of Gria1−/− mice by cannabidiol and hippocampal inhibitory chemogenetics. Front Pharmacol. 2019;10:309.
Gururajan A, Taylor DA, Malone DT. Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague–Dawley rats. J Psychopharmacol. 2012;26(10):152–60.
Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. Cannabinoids in attention-deficit/hyperactivity disorder: a randomized-controlled trial. Eur Neuropsychopharmacol. 2017;27(8):795–808.
Copyright (c) 2026 Arquivos do Mudi
This work is licensed under a Creative Commons Attribution 4.0 International License.
DECLARAÇÃO DE ORIGINALIDADE E DIREITOS AUTORAIS
Declaro que o presente artigo é original, não tendo sido submetido à publicação em qualquer outro periódico nacional ou internacional, quer seja em parte ou em sua totalidade.
Os direitos autorais pertencem exclusivamente aos autores. Os direitos de licenciamento utilizados pelo periódico é a licença Creative Commons Attribution 4.0 (CC BY ): são permitidos o acompartilhamento (cópia e distribuição do material em qualqer meio ou formato) e adaptação (remix, transformação e criação de material a partir do conteúdo assim licenciado para quaisquer fins, inclusive comerciais.
Recomenda-se a leitura desse link para maiores informações sobre o tema: fornecimento de créditos e referências de forma correta, entre outros detalhes cruciais para uso adequado do material licenciado.
